Tsukamura M, Nakamura E, Yoshii S, Amano H
Am Rev Respir Dis. 1985 Mar;131(3):352-6. doi: 10.1164/arrd.1985.131.3.352.
A new antibacterial substance, ofloxacin (DL8280), was used in the treatment of pulmonary tuberculosis. The agent was given to 19 patients with chronic cavitary lung tuberculosis as single doses of 300 mg daily for 6 to 8 months. A decrease in the amount of tubercle bacilli in the sputum was observed in almost all patients, and negative conversion occurred in 5. Resistance of tubercle bacilli to the agent appeared in patients who did not show negative conversion. No side effects were observed during the administration period. The agent was considered useful in lung tuberculosis therapy.
一种新的抗菌物质氧氟沙星（DL8280）被用于治疗肺结核。该药物给予19例慢性空洞型肺结核患者，每日单剂量300mg，持续6至8个月。几乎所有患者痰中结核杆菌数量均减少，5例出现转阴。未转阴患者的结核杆菌对该药物产生了耐药性。给药期间未观察到副作用。该药物被认为对肺结核治疗有用。
